Learn how the Mercosur–EU agreement may reshape Brazil’s IP landscape, strengthening enforcement and influencing patents, trademarks, designs and trade secrets.

A comprehensive outlook on the 2026 regulatory landscape for Brazil's Life Sciences sector, covering CMED pricing, Anvisa's sandbox, and clinical trials.

The Brazilian Superior Court of Justice (STJ) clarifies the application of atypical coercive measures for monetary enforcement under Article 139, IV.

The EU Digital Omnibus simplifies GDPR and AI Act rules, shifting toward a risk-based approach to foster innovation while protecting fundamental data rights.

The BRPTO implements a structural reform under Decree #12,803/2025, focusing on technical specialization and governance to improve IP examination quality in Brazil.

Brazil implements new pricing criteria for technology transfer in Productive Development Partnerships (PDPs) to ensure transparency and SUS fiscal responsibility.

Brazil’s Ministry of Health's SUS Digital call repositions it as an innovation orchestrator, detailing institutional, legal, and IP implications for the HealthTech ecosystem.

Brazil's CMED introduces Rule No. 3/2025, modernizing drug pricing regulation by expanding categories, redefining therapeutic gain, and updating country references.

Brazil's 2025 SEP litigation experienced significant growth, with Rio courts becoming a key forum, marked by procedural innovations, FRAND emphasis, and emerging connected-car disputes.

The BRPTO suspended priority examination for H04 patent applications, effective January 1, 2026, a major shift for telecom and ICT patent prosecution in Brazil.

Brazil's new Private International Law Bill modernizes legal frameworks, focusing on foreign judgment enforcement and intellectual property rights, aiming to align the country with global legal standards and attract investment.

Brazil’s Ministry of Health and ABIFINA partnered on a patent-intelligence agreement to improve patent information use in the SUS, establishing a system akin to the US FDA’s Orange Book.

The article dissects the Apple-EU conflict over the Digital Markets Act, examining the regulation's implications for competition, security, and innovation in tech ecosystems.

The Mariana v. BHP case in the English High Court sets significant precedents for transnational environmental liability, applying Brazilian law to the Fundão Dam collapse.

Brazil's COP30 highlights industrial property's central role in fostering green innovation and a sustainable bioeconomy, crucial for climate leadership and equitable development.

The Brazilian Supreme Court reinterpreted Article 19 of the Civil Rights Framework, introducing a nuanced liability regime for digital platforms to address illegal content dissemination.

The Brazilian Patent Office's draft AI guidelines clarify patentability for AI-assisted inventions in biopharma and agrochemical sectors, emphasizing human contribution.

Brazilian Senate debates Bill No. 4/2025, focusing on Digital Law, neurorights, and 'digital entities' for the new Civil Code, highlighting codification challenges.

Brazil's Decree #12,651/2025 regulates the Clinical Research Act, establishing SINEP and balancing ethics with efficiency, analyzed here in Part 2.

Brazil's Civil Code reform tackles AI interactions, establishing transparency, accountability, and human oversight duties for civil liability in digital environments.

Brazil's proposed Civil Code reform (Bill 4/2025) addresses deepfakes and AI, setting rules for consent, personality rights, and mandatory content labeling.

The proposed reform of Brazil's Civil Code seeks to incorporate AI into civil law, sparking discussions on its impact and coordination with existing AI legislation.

Brazil faces significant regulatory challenges concerning internet anonymity, balancing freedom of expression with the need to combat unlawful practices and hate speech on digital platforms.

A regulação do anonimato digital no Brasil enfrenta desafios, buscando equilibrar liberdade de expressão com responsabilização por conteúdos ilícitos.